GlobalData on MSN1d
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infantsVaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...
Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback